Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07346547

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

CKD Anemia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
  • Patients on hemodialysis (HD) or peritoneal dialysis (PD)
  • Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion criteria

  • Acute Kidney Injury (AKI) without underlying chronicity
  • Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
  • Refusal or inability to provide consent
  • Current enrollment in an interventional trial that restricts real-world data collection
  • Life expectancy < 3 months, where follow-up is not feasible
  • Known contraindications to Daprodustat as per local prescribing information

Treatment and study plan

Daprodustat

Drug

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Primary outcomes

  1. Serum hemoglobin levels

    Time frame: 3 months

    Hemoglobin response to therapy

Secondary outcomes

  1. Frequency of MACE ( Major Adverse Cardiovascular Events)

    Time frame: 3 months

    MACE events:

    • Unstable angina requiring hospitalization
    • Non-fatal MI
    • Non-fatal stroke
    • Cardiovascular death
    • Other adverse events
    • Hospitalization episodes

    . Mortality

    • Optional patient-reported outcomes (fatigue, functional status)

Study contacts

Contact information is provided by the study sponsor or research team.

Hussain Abidi

CONTACT

[email protected]

+923322583236

Sponsors and collaborators

Lead sponsor

Nabiqasim Industries (Pvt) Ltd

Industry

Registry information

Official study title

Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)

Acronym: REDCURE

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 16, 2026
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.